TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06460298: ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Sponsor: ProDa BioTech, LLC · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 51 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06460298 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06460298 Rescue Dossier →